However, fezakinumab (anti-IL-22) showed promise in patients with severe AD and high baseline IL-22 levels in subgroup analyses, while other novel treatments, such as amlitelimab (anti-OX40L), rocatinlimab and telazorlimab (anti-OX40), and nemolizumab (anti-IL-31R), yielded encouraging results. This evidence concerns the gene TNFRSF4 and Alzheimer disease.